Trillium Therapeutics Inc. (Trillium), formerly Stem Cell Therapeutics Corp., is a Canada-based immuno-oncology Company, engaged in developing cancer therapies. The Company has entered into an agreement with the University Health Network (UHN) to gain rights to intellectual property related to the use of tigecycline for the treatment of leukemia, which includes UHN sponsored, open label phase I multicenter dose-escalation tigecycline trial in patients with relapsed or refractory Acute Myeloid Leukemia (AML), which continues to enroll patients. The Company has two pre-clinical programs, SIRPαFc and a CD200 monoclonal antibody (mAb). SIRPαFc is an antibody-like fusion protein that blocks the activity of CD47 and used for the treatment of acute myeloid leukemia (AML) and has broad clinical potential as an immunotherapy for many hematological and solid cancers. CD47 binds SIRPαFc on the surface of macrophages and transmits a signal, which protects cells from macrophage attack.